TW202342478A - 二醯基甘油激酶（ＤＧＫ）α抑制劑及其用途 - Google Patents
二醯基甘油激酶（ＤＧＫ）α抑制劑及其用途 Download PDFInfo
- Publication number
- TW202342478A TW202342478A TW112107273A TW112107273A TW202342478A TW 202342478 A TW202342478 A TW 202342478A TW 112107273 A TW112107273 A TW 112107273A TW 112107273 A TW112107273 A TW 112107273A TW 202342478 A TW202342478 A TW 202342478A
- Authority
- TW
- Taiwan
- Prior art keywords
- heterocycloalkyl
- alkyl
- cycloalkyl
- aryl
- heteroaryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022078655 | 2022-03-01 | ||
| WOPCT/CN2022/078655 | 2022-03-01 | ||
| WOPCT/CN2022/091215 | 2022-05-06 | ||
| CN2022091215 | 2022-05-06 | ||
| WOPCT/CN2022/128282 | 2022-10-28 | ||
| CN2022128282 | 2022-10-28 | ||
| WOPCT/CN2023/071962 | 2023-01-12 | ||
| CN2023071962 | 2023-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202342478A true TW202342478A (zh) | 2023-11-01 |
Family
ID=87883015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112107273A TW202342478A (zh) | 2022-03-01 | 2023-03-01 | 二醯基甘油激酶（ＤＧＫ）α抑制劑及其用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250214990A1 (https=) |
| EP (1) | EP4486745A4 (https=) |
| JP (1) | JP2025507915A (https=) |
| CN (1) | CN118829642A (https=) |
| AR (1) | AR128668A1 (https=) |
| TW (1) | TW202342478A (https=) |
| WO (1) | WO2023165509A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4486741A4 (en) | 2022-03-01 | 2026-04-08 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| WO2025051110A1 (en) * | 2023-09-04 | 2025-03-13 | Insilico Medicine Ip Limited | Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011075747A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Therapeutic compounds |
| KR102767739B1 (ko) * | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| US20230062100A1 (en) * | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| BR112022012179A2 (pt) * | 2019-12-23 | 2022-09-06 | Bristol Myers Squibb Co | Compostos de quinazolina substituída úteis como ativadores de célula t |
| IL294032A (en) * | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| MX2023014762A (es) * | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
-
2023
- 2023-03-01 JP JP2024552219A patent/JP2025507915A/ja active Pending
- 2023-03-01 EP EP23762907.6A patent/EP4486745A4/en active Pending
- 2023-03-01 CN CN202380024556.1A patent/CN118829642A/zh active Pending
- 2023-03-01 WO PCT/CN2023/078973 patent/WO2023165509A1/en not_active Ceased
- 2023-03-01 AR ARP230100508A patent/AR128668A1/es unknown
- 2023-03-01 US US18/841,639 patent/US20250214990A1/en active Pending
- 2023-03-01 TW TW112107273A patent/TW202342478A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118829642A (zh) | 2024-10-22 |
| EP4486745A1 (en) | 2025-01-08 |
| WO2023165509A1 (en) | 2023-09-07 |
| EP4486745A4 (en) | 2026-03-11 |
| AR128668A1 (es) | 2024-06-05 |
| US20250214990A1 (en) | 2025-07-03 |
| JP2025507915A (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7716110B2 (ja) | ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用 | |
| CA3226720A1 (en) | Kras g12d inhibitors and uses thereof | |
| AU2023254280A1 (en) | Fused ring compound, pharmaceutical composition containing same, and use of fused ring compound | |
| TW202342478A (zh) | 二醯基甘油激酶（ＤＧＫ）α抑制劑及其用途 | |
| TW202342477A (zh) | 二醯基甘油激酶(DGK) α抑制劑及其用途 | |
| JP7218431B2 (ja) | 環状ジヌクレオチド類似体、その医薬組成物及び使用 | |
| CN115043836B (zh) | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 | |
| WO2023165525A1 (en) | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof | |
| CN112292374A (zh) | 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途 | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| TW202416963A (zh) | Ｅｇｆｒ抑制劑及其用途 | |
| AU2023224815A1 (en) | Compound as fak inhibitor and use thereof | |
| KR20240093606A (ko) | 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도 | |
| TW202218661A (zh) | 作為ｅｇｆｒ抑制劑的三環化合物 | |
| EA052540B1 (ru) | Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения | |
| JP7384669B2 (ja) | 置換ジヒドロピロロピラゾール化合物および免疫療法剤が組み合わせて投与される医薬組成物 | |
| HK40117800A (zh) | 二酰基甘油激酶(DGK)α抑制剂及其用途 | |
| CN119490507A (zh) | 一种新型激酶抑制剂 | |
| CN120712269A (zh) | Fgfr2和fgfr3的抑制剂及其用途 | |
| HK40055645B (en) | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | |
| HK40055645A (en) | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | |
| HK40032239A (en) | Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof | |
| BR112020001124B1 (pt) | Composto ou o sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e uso do composto ou do sal farmaceuticamente aceitável do mesmo | |
| EA041924B1 (ru) | Аналог циклического динуклеотида, его фармацевтическая композиция и применение |